AR079026A1 - Antagonistas de espiro -oxindol de mdm2 - Google Patents
Antagonistas de espiro -oxindol de mdm2Info
- Publication number
- AR079026A1 AR079026A1 ARP100104201A ARP100104201A AR079026A1 AR 079026 A1 AR079026 A1 AR 079026A1 AR P100104201 A ARP100104201 A AR P100104201A AR P100104201 A ARP100104201 A AR P100104201A AR 079026 A1 AR079026 A1 AR 079026A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- group
- hydrogen
- alkyl
- cycloalkyl
- Prior art date
Links
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 title abstract 2
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 title abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 29
- 239000001257 hydrogen Substances 0.000 abstract 29
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 20
- 150000002431 hydrogen Chemical class 0.000 abstract 15
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
- 125000001072 heteroaryl group Chemical group 0.000 abstract 9
- 125000003107 substituted aryl group Chemical group 0.000 abstract 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 5
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000005518 carboxamido group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- -1 hydroxy, amino Chemical group 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Los compuestos y composiciones proporcionadas en la presente memoria se refieren a espiro-oxindoles que funcionan como antagonistas de la interaccion entre p53 y MDM2, y a su uso como agentes terapéuticos para el tratamiento del cáncer y otras enfermedades. Reivindicacion 1: Un compuesto que tiene la Formula (1): en la que: R1a, R1b, R1c y R1d se seleccionan independientemente entre el grupo que consiste en hidrogeno, halogeno, hidroxi, amino, nitro, ciano, alcoxi, ariloxi, alquilo opcionalmente sustituido, haloalquilo, cicloalquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, cicloalquenilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, carboxamido y sulfonamido; R2 se setecciona entre el grupo que consiste en arilo opcionalmente sustituido y heteroarilo opcionalmente sustituido; R3 se selecciona entre el grupo que consiste en alquilo opcionalmente sustituido, (cicloalquil)alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, cicloalquenilo opcionalmente sustituido, arilo opcionalmente sustituido y heteroarilo opcionalmente sustituido; R4 se selecciona entre el grupo que consiste en hidrogeno y alquilo C1-6 opcionalmente sustituido; R5 se selecciona entre el grupo (2): en el que: cada R6 y R6b se selecciona independientemente entre el grupo que consiste en hidrogeno y alquilo C1-6 opcionalmente sustituido; R7 se selecciona entre el grupo que consiste en hidrogeno, alquilo C1-6 opcionalmente sustituido y cicloalquilo opcionalmente sustituido; cada uno de R8a y R8b se selecciona independientemente entre el grupo que consiste en hidrogeno, alquilo C1-6 opcionalmente sustituido y cicloalquilo opcionalmente sustituido; o R8a y R8b tomados junto con el carbono al que están unidos forman un cicloalquilo opcionalmente sustituido de 3 a 8 miembros; W1 se selecciona entre el grupo que consiste en -OR9a y -NR9bR9c; R9a es hidrogeno; R9b se selecciona entre el grupo que consiste en hidrogeno, alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, -SO2R9d y -CONR9eR9f; R9c se selecciona entre el grupo que consiste en hidrogeno, alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido y heteroarilo opcionalmente sustituido; o R9b y R9c tomados junto con el átomo de nitrogeno al que están unidos forman un heterociclo opcionalmente sustituido de 4 a 8 miembros; R9d se selecciona entre el grupo que consiste en alquilo opcionalmente sustituido y cicloalquilo opcionalmente sustituido; cada uno de R9e y R9f se selecciona independientemente entre el grupo que consiste en hidrogeno, alquilo opcionalmente sustituido y cicloalquilo opcionalmente sustituido; o R9e y R9f tomados junto con el átomo de nitrogeno al que están unidos forman un heterociclo opcionalmente sustituido de 4 a 8 miembros; W2 se selecciona entre el grupo que consiste en -OR10 y -NR11aR11b; R10 es hidrogeno; o uno de R9a y R10 es hidrogeno y el otro es un grupo metabolicamente escindible; con la condicion de que cuando W1 es -OR9a y W2 es -OR10 entonces al menos uno de R7, R8a y R8b sea distinto de hidrogeno; R11a se selecciona entre el grupo que consiste en hidrogeno, alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, -SO2R11c y -CONR11dR11e; Rb se selecciona entre el grupo que consiste en hidrogeno, alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido y heteroarilo opcionalmente sustituido; o R11a y R11b tomados junto con el átomo de nitrogeno al que están unidos forman un heterociclo opcionalmente sustituido de 4 a 8 miembros; R11c se selecciona entre el grupo que consiste en alquilo opcionalmente sustituido y cicloalquilo opcionalmente sustituido; cada uno de R11d y R11e se selecciona independientemente entre el grupo que consiste en hidrogeno, alquilo opcionalmente sustituido y cicloalquilo opcionalmente sustituido; o R11d y R11e junto con el átomo de nitrogeno al que están unidos forman un heterociclo opcionalmente sustituido de 4 a 8 miembros; n es 1, 2, 3, 4 o 5; cada R12a, R12b, R12c y R12d se selecciona independientemente entre el grupo que consiste en hidrogeno y alquilo C1-6 opcionalmente sustituido; R13 se selecciona entre el grupo que consiste en hidrogeno y alquilo C1-6 opcionalmente sustituido; R14 se selecciona entre el grupo que consiste en hidrogeno, alquilo C1-6 opcionalmente sustituido y cicloalquilo opcionalmente sustituido; Z se selecciona entre el grupo que consiste en -OR15 y -NR16aR16b; o Z y R14 tomados juntos forman un grupo carbonilo; R15 se selecciona entre el grupo que consiste en hidrogeno y un grupo metabolicamente escindible; R16b se selecciona entre el grupo que consiste en -SO2R16c y -CONR16dR16e; R16b se selecciona entre el grupo que consiste en hidrogeno y alquilo opcionalmente sustituido; R16c se selecciona entre el grupo que consiste en alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido y heteroarilo opcionalmente sustituido; cada uno de R16d y R16e se selecciona independientemente entre el grupo que consiste en hidrogeno, alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido y heteroarilo opcionalmente sustituido; o R16d y R16e tomados junto con el átomo de nitrogeno al que están unidos forman un heterociclo de 4 a 8 miembros; o es 1, 2 o 3; p es 0, 1, 2 o 3; cada R17a, R17b, R17c y R17d se selecciona independientemente entre el grupo que consiste en hidrogeno y alquilo C1-6 opcionalmente sustituido; R18 se selecciona entre el grupo que consiste en hidrogeno y alquilo C1-6 opcionalmente sustituido; R19 se selecciona entre el grupo que consiste en hidrogeno, alquilo C1-6 opcionalmente sustituido y cicloalquilo opcionalmente sustituido; R20 se selecciona entre el grupo que consiste en hidrogeno, alquilo C1-6 opcionalmente sustituido y cicloalquilo opcionalmente sustituido; cada uno de R21a y R21b es hidrogeno; o uno de R21a y R21b es hidrogeno y el otro es un grupo metabolicamente escindible; q es 0, 1, 2 o 3; r es 1, 2 o 3; X se selecciona entre el grupo que consiste en O, S y NR'; Y se selecciona entre el grupo que consiste en O, S y NRö; R' se selecciona entre el grupo que consiste en hidrogeno, alquilo opcionalmente sustituido, aralquilo y cicloalquilo opcionalmente sustituido; Rö se selecciona entre el grupo que consiste en hidrogeno, alquilo opcionalmente sustituido, aralquilo y cicloalquilo opcionalmente sustituido; y --- representa un enlace sencillo o un doble enlace, o una sal farmacéuticamente aceptable, solvato o profármaco de los mismos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26068509P | 2009-11-12 | 2009-11-12 | |
| US26366209P | 2009-11-23 | 2009-11-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079026A1 true AR079026A1 (es) | 2011-12-21 |
Family
ID=43974649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104201A AR079026A1 (es) | 2009-11-12 | 2010-11-12 | Antagonistas de espiro -oxindol de mdm2 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8518984B2 (es) |
| EP (1) | EP2499145B1 (es) |
| JP (1) | JP2013510860A (es) |
| KR (1) | KR20120099462A (es) |
| CN (2) | CN102712650B (es) |
| AR (1) | AR079026A1 (es) |
| AU (1) | AU2010319595B2 (es) |
| BR (1) | BR112012011317A2 (es) |
| CA (1) | CA2780547C (es) |
| CL (1) | CL2012001250A1 (es) |
| CO (1) | CO6501131A2 (es) |
| CR (1) | CR20120313A (es) |
| DO (1) | DOP2012000131A (es) |
| EC (1) | ECSP12011943A (es) |
| GT (1) | GT201200147A (es) |
| IL (1) | IL219706A (es) |
| MA (1) | MA33815B1 (es) |
| MX (1) | MX2012005507A (es) |
| NI (1) | NI201200083A (es) |
| NZ (1) | NZ600430A (es) |
| PE (1) | PE20121282A1 (es) |
| PH (1) | PH12012500870A1 (es) |
| RU (1) | RU2553269C2 (es) |
| TN (1) | TN2012000161A1 (es) |
| TW (1) | TWI508967B (es) |
| UA (1) | UA107814C2 (es) |
| UY (1) | UY33029A (es) |
| WO (1) | WO2011060049A2 (es) |
| ZA (1) | ZA201203323B (es) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2118123T3 (pl) | 2007-01-31 | 2016-06-30 | Dana Farber Cancer Inst Inc | Stabilizowane peptydy p53 i ich zastosowania |
| KR101525754B1 (ko) | 2007-03-28 | 2015-06-09 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스티칭된 폴리펩티드 |
| JP2013510860A (ja) | 2009-11-12 | 2013-03-28 | ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン | スピロ−オキシインドールｍｄｍ２アンタゴニスト |
| US8088815B2 (en) * | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| SG184288A1 (en) * | 2010-04-09 | 2012-11-29 | Univ Michigan | Biomarkers for mdm2 inhibitors for use in treating disease |
| CA2807685C (en) | 2010-08-13 | 2020-10-06 | Aileron Therapeutics, Inc. | P53 derived peptidomimetic macrocycle |
| TWI535723B (zh) * | 2010-11-12 | 2016-06-01 | 密西根大學董事會 | 螺－吲哚酮ｍｄｍ２拮抗劑 |
| RU2612534C2 (ru) | 2011-03-10 | 2017-03-09 | Дайити Санкио Компани, Лимитед | Диспиропирролидиновые производные |
| SG194873A1 (en) | 2011-05-11 | 2013-12-30 | Sanofi Sa | Spiro-oxindole mdm2 antagonists |
| TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
| EP2788004B1 (en) | 2011-12-07 | 2019-07-03 | Duke University | Methods of identifying and using mdm2 inhibitors |
| BR112014020103A2 (pt) | 2012-02-15 | 2018-10-09 | Aileron Therapeutics, Inc. | macrociclos peptidomiméticos |
| CA2864120A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
| KR20150082307A (ko) | 2012-11-01 | 2015-07-15 | 에일러론 테라퓨틱스 인코포레이티드 | 이치환 아미노산 및 이의 제조 및 사용 방법 |
| BR112015013611A2 (pt) | 2012-12-20 | 2017-11-14 | Merck Sharp & Dohme | composto, e, composição farmacêutica |
| CN103739566B (zh) * | 2014-01-24 | 2016-01-20 | 中国人民解放军第三军医大学 | 含有磺酰胺的手性五元并环骨架化合物及制备方法和用途 |
| CA2945527C (en) | 2014-04-17 | 2022-05-17 | The Regents Of The University Of Michigan | Mdm2 inhibitors and therapeutic methods using the same |
| CN103992334A (zh) * | 2014-05-29 | 2014-08-20 | 中国人民解放军第二军医大学 | 吲哚酮螺四氢硫代吡喃类抗肿瘤衍生物及其制备方法 |
| US10576064B2 (en) | 2014-07-03 | 2020-03-03 | Boehringer Ingelheim International Gmbh | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors |
| WO2016028391A2 (en) * | 2014-08-18 | 2016-02-25 | Hudson Biopharma Inc. | Spiropyrrolidines as mdm2 inhibitors |
| HRP20191414T1 (hr) | 2014-08-21 | 2019-11-01 | Boehringer Ingelheim Int | Novi spojevi i derivati spiro[3h-indol-3,2'-pirolidin]-2(1h)-ona kao mdm1-p53-inhibitori |
| JP6412753B2 (ja) * | 2014-09-19 | 2018-10-24 | 日本テルペン化学株式会社 | 抗菌活性を持つ化合物、およびその製造方法 |
| JP6408318B2 (ja) * | 2014-09-19 | 2018-10-17 | 日本テルペン化学株式会社 | 抗菌活性を持つ化合物、およびその製造方法 |
| MX2017003797A (es) | 2014-09-24 | 2017-06-15 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos y usos de los mismos. |
| SG10201902598VA (en) | 2014-09-24 | 2019-04-29 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and formulations thereof |
| WO2016147205A1 (en) * | 2015-03-13 | 2016-09-22 | Council Of Scientific & Industrial Research | Novel substituted 3-spirophosphoryl pyrazole-2-oxindoles as anti-infectives and process for the synthesis thereof |
| US10253067B2 (en) | 2015-03-20 | 2019-04-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| CN108368161A (zh) | 2015-09-10 | 2018-08-03 | 艾瑞朗医疗公司 | 作为mcl-1调节剂的拟肽大环化合物 |
| US9962380B2 (en) | 2015-09-23 | 2018-05-08 | Wisconsin Alumni Research Foundation | Methods for treating cognitive deficits associated with fragile X syndrome |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| HUE054985T2 (hu) * | 2015-10-09 | 2021-11-29 | Boehringer Ingelheim Int | Spiro[3H-indol-3,2'-pirrolidin]-2(1H)-on vegyületek és számrazékok, mint MDM2-P53 inhibitorok |
| US10759808B2 (en) | 2016-04-06 | 2020-09-01 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| CN113788818A (zh) * | 2016-04-06 | 2021-12-14 | 密执安大学评议会 | Mdm2蛋白质降解剂 |
| CN109152843A (zh) | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| US9822128B1 (en) | 2017-06-01 | 2017-11-21 | King Saud University | Substituted spirooxindoles |
| CN107312115B (zh) * | 2017-06-22 | 2020-06-12 | 北京理工大学 | 一种双吲哚稀土金属催化剂、制备方法及应用 |
| CN109988070B (zh) * | 2017-12-29 | 2022-07-26 | 南京富润凯德生物医药有限公司 | 反式-1-羟基-1-(三氟甲基)-3-氨基环丁烷盐酸盐的中间体及制备方法和应用 |
| KR101857408B1 (ko) | 2018-02-28 | 2018-05-14 | 경북대학교 산학협력단 | 탈모 예방 또는 치료용 조성물 |
| SG11202103282YA (en) | 2018-10-08 | 2021-04-29 | Univ Michigan Regents | Small molecule mdm2 protein degraders |
| GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| MX2022011602A (es) | 2020-03-19 | 2023-01-04 | Kymera Therapeutics Inc | Degradadores de la proteína de homólogo de ratón de minuto 2 (mdm2) y usos de los mismos. |
| US20230313313A1 (en) | 2020-08-27 | 2023-10-05 | Otsuka Pharmaceutical Co., Ltd. | Biomarkers for cancer therapy using mdm2 antagonists |
| EP4247387A1 (en) | 2020-11-23 | 2023-09-27 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| GB202103080D0 (en) | 2021-03-04 | 2021-04-21 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| CN117337327A (zh) * | 2021-04-24 | 2024-01-02 | 通用测序技术公司 | 用于单分子检测的纳米火车 |
| WO2022235605A1 (en) | 2021-05-04 | 2022-11-10 | Enanta Pharmaceuticals, Inc. | Novel macrocyclic antiviral agents |
| US12398147B2 (en) | 2021-05-11 | 2025-08-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic spiropyrrolidine derived antiviral agents |
| US12479854B2 (en) | 2021-07-29 | 2025-11-25 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| WO2023086352A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| WO2023086350A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
| WO2023086400A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| WO2023107419A1 (en) | 2021-12-08 | 2023-06-15 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
| EP4493561A1 (en) * | 2022-03-18 | 2025-01-22 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of substituted spirooxindole derivatives |
| US12145942B2 (en) | 2022-04-05 | 2024-11-19 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US11944604B1 (en) | 2023-03-10 | 2024-04-02 | King Saud University | Nanoformulation of spriooxindole and methods for treating hepatocellular carcinoma |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3219661A (en) * | 1962-12-14 | 1965-11-23 | Warner Lambert Pharmaceutical | Spirooxindole and spirodehydroindole alkaloids and process therefor |
| GB1056537A (en) | 1963-07-16 | 1967-01-25 | Smith Kline French Lab | Improvements in or relating to crystalline alkaloids of mitragyna citiata and compositions thereof |
| JPS444986Y1 (es) | 1966-10-20 | 1969-02-24 | ||
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4444762A (en) | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
| JPH044986A (ja) | 1990-04-20 | 1992-01-09 | Nippon Stainless Steel Co Ltd | ニッケル・ステンレス鋼クラッド材の製造方法 |
| US6605712B1 (en) | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
| RU2084449C1 (ru) | 1994-03-02 | 1997-07-20 | Всероссийский научный центр по безопасности биологически активных веществ | 1-бензил-2-оксотриптамин гидрохлорид и его производные, обладающие гепатозащитной активностью |
| US5773455A (en) | 1996-06-28 | 1998-06-30 | Biomeasure, Incorporated | Inhibitors of prenyl transferases |
| US7083983B2 (en) | 1996-07-05 | 2006-08-01 | Cancer Research Campaign Technology Limited | Inhibitors of the interaction between P53 and MDM2 |
| ATE467418T1 (de) * | 1997-01-20 | 2010-05-15 | Immodal Pharmaka Gmbh | Verfahren und stoffe zur freisetzung eines wachstumsfaktors aus endothelzellen, und nach dem verfahren freigesetzter wachstumsfaktor sowie seine verwendung |
| AU9307098A (en) | 1997-09-08 | 1999-03-29 | Arqule, Inc. | Spiro{pyrrolidine-2,3'-oxindole} compounds and methods of use |
| US7125659B1 (en) | 1998-08-20 | 2006-10-24 | Chugai Seiyaku Kabushiki Kaisha | Method and screening candidate compounds for drug against tumor |
| US7205404B1 (en) | 1999-03-05 | 2007-04-17 | Metabasis Therapeutics, Inc. | Phosphorus-containing prodrugs |
| US6831155B2 (en) | 1999-12-08 | 2004-12-14 | President And Fellows Of Harvard College | Inhibition of p53 degradation |
| CN1182083C (zh) | 2001-10-08 | 2004-12-29 | 廖宜芳 | 一种杀虫灭菌的配位肥及其制造方法 |
| RU2305095C2 (ru) | 2001-12-18 | 2007-08-27 | Ф.Хоффманн-Ля Рош Аг | Цис-2,4,5-трифенилимидазолины и фармацевтическая композиция на их основе |
| JP4361798B2 (ja) | 2001-12-18 | 2009-11-11 | エフ．ホフマン−ラ ロシュ アーゲー | Ｍｄｍ２インヒビターとしてのシス−イミダゾリン |
| JP4023184B2 (ja) | 2002-03-11 | 2007-12-19 | 昭和電工株式会社 | 発光体粒子及びその製造方法並びにその用途 |
| WO2003106384A2 (en) | 2002-06-01 | 2003-12-24 | Johns Hopkins University | Novel boronic chalcone derivatives and uses thereof |
| WO2004043371A2 (en) | 2002-11-08 | 2004-05-27 | Irm Llc | Methods and compositions for modulating p53 transcription factor |
| US20050227932A1 (en) | 2002-11-13 | 2005-10-13 | Tianbao Lu | Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction |
| EP1633749A4 (en) | 2003-02-13 | 2011-03-02 | Us Gov Health & Human Serv | Deazaflavin compounds and methods of use thereof |
| US6916833B2 (en) | 2003-03-13 | 2005-07-12 | Hoffmann-La Roche Inc. | Substituted piperidines |
| US7425638B2 (en) | 2003-06-17 | 2008-09-16 | Hoffmann-La Roche Inc. | Cis-imidazolines |
| US7132421B2 (en) | 2003-06-17 | 2006-11-07 | Hoffmann-La Roche Inc. | CIS-imidazoles |
| US7589233B2 (en) | 2003-07-29 | 2009-09-15 | Signature R&D Holdings, Llc | L-Threonine derivatives of high therapeutic index |
| US8173840B2 (en) | 2003-07-29 | 2012-05-08 | Signature R&D Holdings, Llc | Compounds with high therapeutic index |
| CA2534342C (en) | 2003-07-29 | 2016-05-10 | V. Ravi Chandran | Amino acid prodrugs |
| US7829742B2 (en) | 2003-12-22 | 2010-11-09 | Johns Hopkins University | Boronic acid aryl analogs |
| US8598127B2 (en) | 2004-04-06 | 2013-12-03 | Korea Research Institute Of Bioscience & Biotechnology | Peptides for inhibiting MDM2 function |
| TWI350168B (en) | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
| CN1953965B (zh) | 2004-05-18 | 2012-07-04 | 霍夫曼-拉罗奇有限公司 | 新型顺式咪唑啉类化合物 |
| GB0419481D0 (en) | 2004-09-02 | 2004-10-06 | Cancer Rec Tech Ltd | Isoindolin-1-one derivatives |
| DK1809622T3 (da) | 2004-09-22 | 2010-11-08 | Janssen Pharmaceutica Nv | Inhibitorer af interaktionen mellem MDM2 og P53 |
| SG176463A1 (en) | 2005-02-22 | 2011-12-29 | Univ Michigan | Small molecule inhibitors of mdm2 and uses thereof |
| KR100944301B1 (ko) * | 2005-02-22 | 2010-02-24 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Ｍｄｍ２의 소분자 억제제 및 이의 용도 |
| ZA200709819B (en) | 2005-05-24 | 2009-09-30 | Serono Lab | Tricyclic spiro derivatives as CRTH2 modulators |
| US7576082B2 (en) * | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
| US7495007B2 (en) * | 2006-03-13 | 2009-02-24 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| CN101400680B (zh) * | 2006-03-13 | 2012-04-25 | 霍夫曼-拉罗奇有限公司 | 螺吲哚满酮衍生物 |
| EP2001868B1 (en) | 2006-03-22 | 2013-07-17 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between mdm2 and p53 |
| US8222288B2 (en) | 2006-08-30 | 2012-07-17 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
| CA2661354C (en) * | 2006-08-30 | 2012-12-18 | The Regents Of The University Of Michigan | New small molecule inhibitors of mdm2 and the uses thereof |
| US7737174B2 (en) * | 2006-08-30 | 2010-06-15 | The Regents Of The University Of Michigan | Indole inhibitors of MDM2 and the uses thereof |
| US8002528B2 (en) * | 2006-09-18 | 2011-08-23 | Emerson Climate Technologies, Inc. | Compressor assembly having vibration attenuating structure |
| JP2010504298A (ja) * | 2006-09-21 | 2010-02-12 | エフ．ホフマン−ラ ロシュ アーゲー | オキシンドール誘導体 |
| US7638548B2 (en) * | 2006-11-09 | 2009-12-29 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| JPWO2008072655A1 (ja) | 2006-12-14 | 2010-04-02 | 第一三共株式会社 | イミダゾチアゾール誘導体 |
| WO2008106507A2 (en) | 2007-02-27 | 2008-09-04 | University Of South Florida | Mdm2/mdmx inhibitor peptide |
| AR065860A1 (es) | 2007-03-29 | 2009-07-08 | Novartis Ag | 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas |
| US7625895B2 (en) | 2007-04-12 | 2009-12-01 | Hoffmann-Le Roche Inc. | Diphenyl-dihydro-imidazopyridinones |
| WO2008130614A2 (en) | 2007-04-20 | 2008-10-30 | University Of Pittsburg-Of The Commonwealth System Of Higher Education | Selective and dual-action p53/mdm2/mdm4 antagonists |
| US7553833B2 (en) * | 2007-05-17 | 2009-06-30 | Hoffmann-La Roche Inc. | 3,3-spiroindolinone derivatives |
| US7834179B2 (en) * | 2007-05-23 | 2010-11-16 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| AU2008300483B2 (en) | 2007-09-21 | 2013-01-10 | Janssen Pharmaceutica Nv | Inhibitors of the interaction between MDM2 and p53 |
| RU2360914C1 (ru) * | 2007-10-31 | 2009-07-10 | Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" | Анальгетическое средство |
| CZ301561B6 (cs) | 2007-12-04 | 2010-04-14 | Výzkumný ústav živocišné výroby, v. v. i. | Prostredek pro prevenci a potlacování kokcidióz |
| US8134001B2 (en) * | 2007-12-14 | 2012-03-13 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| US7776875B2 (en) * | 2007-12-19 | 2010-08-17 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
| US7723372B2 (en) * | 2008-03-19 | 2010-05-25 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
| WO2009151069A1 (ja) | 2008-06-12 | 2009-12-17 | 第一三共株式会社 | ４，７－ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体 |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| US7928233B2 (en) * | 2009-02-10 | 2011-04-19 | Hoffmann-La Roche Inc. | Spiroindolinone pyridine derivatives |
| US8076482B2 (en) * | 2009-04-23 | 2011-12-13 | Hoffmann-La Roche Inc. | 3,3′-spiroindolinone derivatives |
| JP2013510860A (ja) | 2009-11-12 | 2013-03-28 | ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン | スピロ−オキシインドールｍｄｍ２アンタゴニスト |
| US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| US8288431B2 (en) | 2010-02-17 | 2012-10-16 | Hoffmann-La Roche Inc. | Substituted spiroindolinones |
| WO2011106650A2 (en) | 2010-02-27 | 2011-09-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease |
| SG184288A1 (en) * | 2010-04-09 | 2012-11-29 | Univ Michigan | Biomarkers for mdm2 inhibitors for use in treating disease |
| US8217044B2 (en) * | 2010-04-28 | 2012-07-10 | Hoffmann-La Roche Inc. | Spiroindolinone pyrrolidines |
| US20120046306A1 (en) | 2010-08-18 | 2012-02-23 | David Joseph Bartkovitz | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists |
| US20120071499A1 (en) | 2010-09-20 | 2012-03-22 | Xin-Jie Chu | Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones |
| TWI535723B (zh) * | 2010-11-12 | 2016-06-01 | 密西根大學董事會 | 螺－吲哚酮ｍｄｍ２拮抗劑 |
| SG194873A1 (en) | 2011-05-11 | 2013-12-30 | Sanofi Sa | Spiro-oxindole mdm2 antagonists |
-
2010
- 2010-11-10 JP JP2012538940A patent/JP2013510860A/ja active Pending
- 2010-11-10 PE PE2012000616A patent/PE20121282A1/es not_active Application Discontinuation
- 2010-11-10 BR BR112012011317A patent/BR112012011317A2/pt not_active IP Right Cessation
- 2010-11-10 RU RU2012124056/04A patent/RU2553269C2/ru not_active IP Right Cessation
- 2010-11-10 AU AU2010319595A patent/AU2010319595B2/en not_active Ceased
- 2010-11-10 UA UAA201207063A patent/UA107814C2/uk unknown
- 2010-11-10 MX MX2012005507A patent/MX2012005507A/es active IP Right Grant
- 2010-11-10 CN CN201080061294.9A patent/CN102712650B/zh not_active Expired - Fee Related
- 2010-11-10 PH PH1/2012/500870A patent/PH12012500870A1/en unknown
- 2010-11-10 EP EP10830642.4A patent/EP2499145B1/en not_active Not-in-force
- 2010-11-10 CN CN201510186334.7A patent/CN104876938A/zh active Pending
- 2010-11-10 KR KR1020127015095A patent/KR20120099462A/ko not_active Withdrawn
- 2010-11-10 CA CA2780547A patent/CA2780547C/en not_active Expired - Fee Related
- 2010-11-10 NZ NZ600430A patent/NZ600430A/en not_active IP Right Cessation
- 2010-11-10 WO PCT/US2010/056197 patent/WO2011060049A2/en not_active Ceased
- 2010-11-11 TW TW099138770A patent/TWI508967B/zh not_active IP Right Cessation
- 2010-11-12 US US12/945,511 patent/US8518984B2/en not_active Expired - Fee Related
- 2010-11-12 UY UY0001033029A patent/UY33029A/es not_active Application Discontinuation
- 2010-11-12 AR ARP100104201A patent/AR079026A1/es unknown
-
2012
- 2012-04-04 TN TNP2012000161A patent/TN2012000161A1/en unknown
- 2012-05-03 NI NI201200083A patent/NI201200083A/es unknown
- 2012-05-07 ZA ZA2012/03323A patent/ZA201203323B/en unknown
- 2012-05-09 IL IL219706A patent/IL219706A/en not_active IP Right Cessation
- 2012-05-10 DO DO2012000131A patent/DOP2012000131A/es unknown
- 2012-05-11 GT GT201200147A patent/GT201200147A/es unknown
- 2012-05-11 CL CL2012001250A patent/CL2012001250A1/es unknown
- 2012-06-01 EC ECSP12011943 patent/ECSP12011943A/es unknown
- 2012-06-08 CR CR20120313A patent/CR20120313A/es unknown
- 2012-06-11 MA MA34958A patent/MA33815B1/fr unknown
- 2012-06-12 CO CO12098587A patent/CO6501131A2/es active IP Right Grant
-
2013
- 2013-07-17 US US13/944,587 patent/US8877796B2/en not_active Expired - Fee Related
-
2014
- 2014-09-12 US US14/485,054 patent/US9079913B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR079026A1 (es) | Antagonistas de espiro -oxindol de mdm2 | |
| MX2021006618A (es) | Esteroides neuroactivos y sus metodos de uso. | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| NZ749714A (en) | C7, c12, and c16 substituted neuroactive steroids and their methods of use | |
| CY1124631T1 (el) | 11-υποκατεστημενες 24-υδροξυστερολες για χρηση στην αγωγη nmda σχετιζομενων παθησεων | |
| AR068840A1 (es) | Moduladores del gpr40 bifenilo sustituidos y composiciones farmaceuticas que los contienen | |
| PE20141788A1 (es) | Derivados de betulina | |
| JOP20210005A1 (ar) | عوامل تحلل مستقبلات الإستروجين الانتقائية | |
| PE20080144A1 (es) | Compuestos de tetrahidropiridotienopirimidina con actividad antiproliferativa | |
| AR035548A1 (es) | Compuestos organicos | |
| MA32711B1 (fr) | Pyrrolidine-2-carboxamides substitues | |
| AR040500A1 (es) | Inhibidores de cinasas | |
| PH12021551257A1 (en) | Cyclic pantetheine derivatives and uses thereof | |
| IL189191A0 (en) | Thiazolyl piperidine derivatives useful as h3 receptor modulators | |
| JP2011517453A5 (es) | ||
| PE20090890A1 (es) | Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c | |
| AR064253A1 (es) | Compuestos de biciclocarboxiamida sustituidos composiciones farmaceuticas y una combinacion que los incluye y su uso en fabaricacion de un medicamento para el tratamiento de enfermedades mediadas por la actividad del receptor vr1 | |
| MY148988A (en) | Terphenyl derivatives for treatment of alzheimer's disease | |
| PE20140792A1 (es) | Composiciones farmaceuticas | |
| AR067075A1 (es) | Derivados de isoxasol - imidazol | |
| CY1116391T1 (el) | Αιθινυλο παραγωγα ως θετικοι αλλοστερικοι ρυθμιστες του mglur5 | |
| PE20171443A1 (es) | Derivados de carboxamida | |
| UY27803A1 (es) | Derivados de benzoxazina y usos de los mismos. | |
| AR055554A1 (es) | Compuestos piridinicos, composicion farmaceutica y uso de los compuestos para preparar medicamentos | |
| TW200716547A (en) | Piperidin-4-yl-amide derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |